Keith Mayl

Keith Mayl, MD, PhD, is a Senior Medical Director specializing in Clinical Development for the Global ALS Indication at argenx since July 2025. Prior experience includes serving as Senior Clinical Development Lead in Neurology at Servier, where Keith focused on RNA-targeting therapies for rare neurological diseases. Keith's academic background includes a position as Clinical Research Physician in Neurology and Doctoral Researcher in Gene Therapy at King's College London, with research centered on viral vector-based gene therapy for ALS-FTD. Additional roles have included Honorary Specialist Registrar in Neurology at King's College Hospital and Clinical Fellow in Neurology at University College London Hospitals, complemented by clinical training as a Foundation Doctor in various specialties. Keith obtained a Doctor of Philosophy in Clinical Neuroscience from King's College London and a Doctor of Medicine from the University of Malta.